BiOrion Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 4

Employees

  • Latest Deal Type
  • M&A

BiOrion General Information

Description

Developer of radiopharmaceuticals, radiotherapeutics, and imaging diagnostics designed to treat patients with fibrosis and fibrotic cancer. The company's tracers are based on single-domain antibodies recognizing the extracellular domains of the membrane receptors of activated myofibroblasts, the key pathogenic cells in lung fibrosis, cardiac fibrosis, kidney fibrosis, hepatic fibrosis, and fibrotic cancers such as colon cancer, enabling healthcare professionals to diagnose and treat patients with high medical need and urgency.

Contact Information

Website
www.biorion.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • MediTech Center
  • L.J. Zielstraweg 1
  • 9713 GX Groningen
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • MediTech Center
  • L.J. Zielstraweg 1
  • 9713 GX Groningen
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BiOrion Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Merger/Acquisition 01-Jul-2023 Completed Clinical Trials - Phase 2
15. IPO Cancelled Clinical Trials - Phase 2
14. Later Stage VC Cancelled Clinical Trials - Phase 2
13. Later Stage VC (Series A) Cancelled Clinical Trials - Phase 2
12. Later Stage VC Completed Clinical Trials - Phase 2
11. Later Stage VC 22-Feb-2022 Completed Clinical Trials - Phase 2
10. Grant 22-Apr-2021 Completed Clinical Trials - Phase 2
9. Later Stage VC 20-Feb-2019 Completed Clinical Trials - Phase 1
8. Later Stage VC 19-Feb-2019 $264K $2.44M Completed Pre-Clinical Trials
7. Grant 14-Sep-2017 $571K $2.18M Completed Pre-Clinical Trials
To view BiOrion’s complete valuation and funding history, request access »

BiOrion Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of radiopharmaceuticals, radiotherapeutics, and imaging diagnostics designed to treat patients with fibrosis a
Drug Discovery
Groningen, Netherlands
4 As of 2025

Oxford, United Kingdom
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BiOrion Competitors (45)

One of BiOrion’s 45 competitors is Blue Earth Diagnostics, a Formerly VC-backed company based in Oxford, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Blue Earth Diagnostics Formerly VC-backed Oxford, United Kingdom
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Regenerx Formerly VC-backed Rockville, MD
Cullinan Therapeutics Formerly VC-backed Cambridge, MA
Kite Pharma Formerly VC-backed Santa Monica, CA
You’re viewing 5 of 45 competitors. Get the full list »

BiOrion Patents

BiOrion Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4100437-A1 Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof Inactive 07-Feb-2020
US-20240174755-A1 Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof Inactive 07-Feb-2020
WO-2021158110-A1 Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof Inactive 07-Feb-2020
CA-3170712-A1 Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof. Pending 07-Feb-2020
US-10442845-B2 Interferon analogs Inactive 10-Feb-2010 A61K38/217
To view BiOrion’s complete patent history, request access »

BiOrion Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BiOrion Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Carduso Capital Venture Capital Minority
European Commission Government Minority
Eurostars Other Minority
GJ Smid Fonds Venture Capital Minority
Hanzepoort Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

BiOrion FAQs

  • When was BiOrion founded?

    BiOrion was founded in 2007.

  • Where is BiOrion headquartered?

    BiOrion is headquartered in Groningen, Netherlands.

  • What is the size of BiOrion?

    BiOrion has 4 total employees.

  • What industry is BiOrion in?

    BiOrion’s primary industry is Drug Discovery.

  • Is BiOrion a private or public company?

    BiOrion is a Private company.

  • What is BiOrion’s current revenue?

    The current revenue for BiOrion is .

  • How much funding has BiOrion raised over time?

    BiOrion has raised $5.92M.

  • Who are BiOrion’s investors?

    Carduso Capital, European Commission, Eurostars, GJ Smid Fonds, and Hanzepoort are 5 of 8 investors who have invested in BiOrion.

  • Who are BiOrion’s competitors?

    Blue Earth Diagnostics, Inovio Pharmaceuticals, Regenerx, Cullinan Therapeutics, and Kite Pharma are some of the 45 competitors of BiOrion.

  • When was BiOrion acquired?

    BiOrion was acquired on 01-Jul-2023.

  • Who acquired BiOrion?

    BiOrion was acquired by Cortalix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process